{"id":685773,"date":"2024-01-25T14:26:01","date_gmt":"2024-01-25T14:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685773"},"modified":"2024-01-25T14:26:01","modified_gmt":"2024-01-25T14:26:01","slug":"verzenio-abemaciclib-for-er-ve-her2ve-breast-cancer-market-size-and-share-analysis-and-competitive-landscape-by-delveinsight-key-players-eli-lilly-and-company","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/verzenio-abemaciclib-for-er-ve-her2ve-breast-cancer-market-size-and-share-analysis-and-competitive-landscape-by-delveinsight-key-players-eli-lilly-and-company_685773.html","title":{"rendered":"Verzenio (Abemaciclib) for ER +ve HER2-ve Breast Cancer: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players – Eli Lilly and Company"},"content":{"rendered":"
\n
\"Verzenio<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight has recently published a report on \u201cVerzenio (Abemaciclib) Market Forecast Report\u201d providing an in-depth analysis of the Verzenio (Abemaciclib) market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/div>\n

The comprehensive report provides an analysis of Verzenio (Abemaciclib) market potential and market share analysis in the ER +ve HER2-ve Breast Cancer therapeutics space across the 7MM from 2019 to 2032. The report also helps you to understand the Verzenio (Abemaciclib) clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.<\/em><\/p>\n

Verzenio (Abemaciclib) Drug Insights<\/strong><\/a><\/p>\n

VERZENIO (Abemaciclib) is prescribed for the treatment of women with hormone receptor-positive (HR+) breast cancer when used in conjunction with fulvestrant. It is also employed in the management of advanced or metastatic breast cancer that is hormone receptor-positive (HR+), HER2-negative (HER2-), and has progressed following endocrine therapy. Furthermore, as a monotherapy, VERZENIO is administered to adult patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced or metastatic breast cancer that has experienced progression after both endocrine therapy and prior chemotherapy in the metastatic setting.<\/p>\n

For combined therapy with fulvestrant, the recommended dosage of VERZENIO is 150 mg administered orally twice daily. In instances where VERZENIO is utilized as monotherapy, the recommended dosage is 200 mg taken orally twice daily. The treatment regimen is advised to be continued until there is evidence of disease progression or the emergence of unacceptable toxicity. It is noteworthy that VERZENIO can be taken either with or without food, providing flexibility in its administration.<\/p>\n

Stay ahead of the competition by leveraging key insights and evolving trends in the Verzenio (Abemaciclib) market @ <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/verzenio-abemaciclib-drug-insight-market-forecast<\/strong><\/a><\/p>\n

Key Highlights of the Verzenio (Abemaciclib) Market Report<\/strong><\/p>\n